Rexahn Pharmaceuticals Inc. (RNN)

6.13
0.04 0.65
AMEX : Health Technology
Prev Close 6.17
Open 6.12
Day Low/High 5.80 / 6.35
52 Wk Low/High 0.50 / 2.38
Volume 104.64K
Avg Volume 1.03M
Exchange AMEX
Shares Outstanding 4.02M
Market Cap 25.11M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action

Rexahn Pharmaceuticals Announces The Publication Of Preclinical Data For Supinoxin(TM) (RX-5902) Demonstrating Mechanism Of Action

Supinoxin(TM) Phase I Clinical Trial in Cancer Patients is Ongoing and is Expected to be Completed in the First Half of 2015

Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells

Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For RX-3117 Demonstrating Effectiveness Against Gemcitabine Resistant Human Cancer Cells

RX-3117 Phase Ib Clinical Trial in Cancer Patients Is Ongoing and Is Expected to Be Completed in Early 2015

Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results And Pipeline Update

Rexahn Pharmaceuticals Reports Third Quarter 2014 Financial Results And Pipeline Update

Encouraging Data From Dose-Escalation Studies, Plus FDA Orphan Drug Designation in Pancreatic Cancer

Rexahn Pharmaceuticals To Present At The BioPharm America™ 2014 In Boston, Massachusetts, USA

Rexahn Pharmaceuticals To Present At The BioPharm America™ 2014 In Boston, Massachusetts, USA

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, PhD, Director of Business...

Rexahn Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference On September 9, 2014

Rexahn Pharmaceuticals To Present At The 16th Annual Rodman & Renshaw Global Investment Conference On September 9, 2014

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D.

Rexahn Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform

Rexahn Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the...

Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results And Pipeline Update

Rexahn Pharmaceuticals Reports Second Quarter 2014 Financial Results And Pipeline Update

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development...

Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors

Rexahn Pharmaceuticals Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced an update in its Phase I multi-center...

Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results And Pipeline Update

Rexahn Pharmaceuticals Reports First Quarter 2014 Financial Results And Pipeline Update

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development...

RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).

RX-3117 Showed Greater Efficacy (tumor Growth Inhibition) As Compared To Gemcitabine In Four Different Xenograft Animal Models With Gemcitabine Resistant Human Cancer Cell Lines: Colorectal Cancer (Colo205), Small Cell Lung Cancer (H69), Cervical Cancer (CaSki) And Pancreatic Cancer (CTG-0298).

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced additional data from preclinical studies on the...

Rexahn Presents Data From Preclinical Studies Of RX-21101

Rexahn Presents Data From Preclinical Studies Of RX-21101

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced promising preclinical results for RX-21101, the...

Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting

Rexahn Pharmaceuticals To Present Data On RX-3117 And RX-21101 At The 2014 American Association For Clinical Research Annual Meeting

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at...

Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results And Recent Highlights

Rexahn Pharmaceuticals Reports Fourth Quarter And Full-Year 2013 Financial Results And Recent Highlights

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development...

3 Stocks Under $10 Making Big Moves

3 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Rexahn Pharmaceuticals To Present At The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum In New York

Rexahn Pharmaceuticals To Present At The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum In New York

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Vikas Sharma, Ph.

Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors

Rexahn Announces Initial Results From Phase I Trial Of SupinoxinTM (RX-5902) For Solid Cancer Tumors

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of Supinoxin TM (RX-5902) initiated in August 2013.

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Rexahn Pharmaceuticals To Present At The 26th Annual ROTH Conference

Rexahn Pharmaceuticals To Present At The 26th Annual ROTH Conference

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company’s...